A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab

This study has been completed.
Information provided by:
Centocor, Inc.
ClinicalTrials.gov Identifier:
First received: December 30, 2005
Last updated: April 23, 2010
Last verified: April 2010

The purpose of this study is to compare the effectiveness and safety of intracoronary stenting with or without abciximab, an anti-platelet therapy, and conventional coronary angioplasty with abciximab in patients undergoing percutaneous coronary intervention.

Condition Intervention Phase
Angioplasty, Transluminal, Percutaneous Coronary
Drug: Abciximab/angioplasty, abciximab/stent, placebo/stent
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percutaneous Coronary Intervention

Resource links provided by NLM:

Further study details as provided by Centocor, Inc.:

Primary Outcome Measures:
  • Composite of deaths, myocardial infarctions, or urgent repeat revascularizations within 30 days of randomization

Secondary Outcome Measures:
  • Six-month clinical outcome; Six-month angiographic outcome as determined by quantitative coronary angiography in a subgroup of patients; Health economic analyses of medical costs, medical resource consumption, and cost effectiveness

Estimated Enrollment: 2400
Detailed Description:

This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and effectiveness of intracoronary stenting with or without abciximab, an anti-platelet therapy, and conventional coronary angioplasty with abciximab in patients undergoing percutaneous coronary intervention. Patients will be randomly assigned to one of three treatment groups: coronary angioplasty plus abciximab, intracoronary stent plus abciximab, or intracoronary stent plus placebo. The primary measures of effectiveness will be a 30-day composite, clinical outcome as determined by the number of deaths, myocardial infarctions, or urgent repeat revascularizations. Please see attached results.

Patients will receive one of three different treatments: Coronary angioplasty plus abciximab; Intracoronary stent plus abciximab; or Intracoronary stent plus placebo.


Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients referred for elective or urgent percutaneous coronary intervention
  • Who are suitable candidates for either conventional angioplasty or primary intracoronary stent implantation
  • Having a target artery (native or graft) stenosis of >= 60% (visual estimation)

Exclusion Criteria:

  • Patients with acute ST-segment elevation myocardial infarction within the previous 12 hours
  • With a planned staged procedure or having an unprotected left main coronary artery stenosis > 50%
  • With active internal bleeding, having a condition that may increase the risk of bleeding, or receiving ongoing treatment with an oral anticoagulant at the time of study entry
  • Having had a percutaneous coronary intervention within the previous 3 months or prior intracoronary stent placement in a target vessel
  • Having hypertension with systolic blood pressure > 180 mm Hg or diastolic blood pressure > 100 mm Hg at the time of study entry, or a platelet count < 100,000/μL at baseline
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00271401

Sponsors and Collaborators
Centocor, Inc.
Study Director: Centocor, Inc. Clinical Trial Centocor, Inc.
  More Information

ClinicalTrials.gov Identifier: NCT00271401     History of Changes
Other Study ID Numbers: CR006265
Study First Received: December 30, 2005
Last Updated: April 23, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Centocor, Inc.:
Angioplasty, Transluminal, Percutaneous Coronary

Additional relevant MeSH terms:
Hematologic Agents
Pharmacologic Actions
Platelet Aggregation Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on May 21, 2015